Corcept Therapeutics Faces Class Action Lawsuit After FDA Rejection and Patent Setback

Corcept Therapeutics Faces Legal Challenges

Corcept Therapeutics, Inc. (NASDAQ: CORT), known for its development of treatments for various conditions, is currently facing a serious securities class action lawsuit. This comes on the heels of a recent FDA rejection of its flagship drug, relacorilant, and a notable defeat regarding patent protections. The law firm Hagens Berman has issued a reminder to shareholders regarding the critical deadlines for participation in the pending lawsuit.

Overview of the Situation

The lawsuit highlights a troubling narrative involving the management of Corcept, which allegedly misled investors about the viability of relacorilant by not disclosing critical information provided by the FDA during their communications. As these revelations became public, they have caused a dramatic decline in Corcept's stock value. On December 31, 2025, the company announced it received a Complete Response Letter (CRL) from the FDA, signaling its inability to approve the drug based on the evidence presented. This letter had a devastating effect on the company’s market valuation, erasing nearly $2.5 billion overnight as the stock price tumbled from $70.20 to $34.80.

Key Allegations

The lawsuit focuses on multiple allegations against Corcept Therapeutics, including:
1. Concealment of Information: It is claimed that the company management concealed critical warnings from the FDA regarding the insufficiency of clinical data that underpins their confidence in relacorilant's approval.
2. Misrepresentation of Data: Throughout 2024 and 2025, Corcept's communications suggested that the drug was in a favorable position for approval despite knowing that the data was fundamentally flawed.
3. Market Response: The management allegedly instilled an aura of optimism that did not reflect the reality of the data received from the FDA, misleading investors and ultimately leading to drastic market consequences when the truth emerged.

Legal Proceedings

The lawsuit’s timeline indicates that investors who incurred losses during the defined class period (October 31, 2024, to December 30, 2025) must act quickly. The law firm has set a lead plaintiff deadline of April 21, 2026. Therefore, affected shareholders have a limited timeframe to file claims to seek potential restitution.

The legal filing, identified as Allegheny County Employees Retirement System v. Corcept Therapeutics Inc., et al., is registered under the case number 26-cv-01525 in the Northern District of California. Those affected by the class period losses are encouraged to reach out for more information and consider their positions in the upcoming legal actions.

Conclusion

As Corcept navigates this precarious situation, the impact on shareholders has been profound and immediate. The failed drug approval along with a federal court ruling against the company illustrates the precarious nature of relying on emerging therapies, along with the requisite responsibilities of transparency to shareholders. It's imperative for investors to stay informed and consider their options moving forward as developments unfold. Additional resources, including guidance for whistleblowers with insider information about Corcept, are available to those looking to take action.

Stay tuned to further developments as this significant legal situation unwinds, and consider consulting with legal advisors if you are an investor in Corcept Therapeutics.